Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636176 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
A Phase 3 study of Heart Failure, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,600
- Enrollment target
- 20
- Study locations
NCT05636176: Recruiting Phase 3 study of Heart Failure, sponsored by Novo Nordisk A/S.
NCT05636176 is a Phase 3 study of Heart Failure that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 5,600 participants, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (175% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05636176, a Phase 3 study of Heart Failure, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
Primary Outcome
Measured in months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ziltivekimab
Study Locations (20)
California
- InvivoCure -2 - Alhambra
- National Heart Institute Cal - Beverly Hills
- Valley Clinical Trials - Covina
- Scripps Memorial Hospital La Jolla - La Jolla
- Purushotham & Akther Kotha MD, inc. - La Mesa
- VA Loma Linda Hlthcr Sys - Loma Linda
- Biopharma Clinical Research Services, LLC - Los Angeles
- VA Greater Los Angeles Hlthcare System - Los Angeles
- VAGrtrLosAngelesHlthcareSystem - Los Angeles
- Valley Clinical Trials, Inc. - Northridge
- UCI Health - Orange
- Stanford Univ School of Med - Palo Alto
- San Diego Cardiac Center - San Diego
- North America Research Institute - San Dimas
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- Eastern Shore Rsrch Inst, LLC - Fairhope
- Heart Center Rsrch_Hunstville - Huntsville
Arizona
- Banner University Medical Ctr - Phoenix
- Banner University Medical Ctr - Phoenix
Arkansas
- Cardiology & Medicine Clinic - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,600 participants |
| Start Date | 2023-05-08 |
| Est. Completion | 2027-07-02 |
| Phase | Phase 3 |
What NCT05636176 shows while recruiting
NCT05636176 is an interventional study that assigns participants to a tested intervention. Its 5,600 participants enrollment target places it among the larger protocols in the corpus, above the 2,035-participant average among 397 other Heart Failure trials with a reported enrollment target (175% higher).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05636176 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05636176 about?
NCT05636176 is a clinical study titled "A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation". This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine in...
What is the current status of trial NCT05636176?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,600 participants. The study started on 2023-05-08. Estimated completion is 2027-07-02.
What conditions does trial NCT05636176 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05636176?
The interventions under investigation include: Placebo (DRUG), Ziltivekimab (DRUG).
Who is sponsoring clinical trial NCT05636176?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636176 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05636176's enrollment target sits among peer trials
5,600 15th of 397 higher than 383 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI